



## Complete Summary

---

### GUIDELINE TITLE

Pregnancy and breast cancer.

### BIBLIOGRAPHIC SOURCE(S)

Royal College of Obstetricians and Gynaecologists (RCOG). Pregnancy and breast cancer. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2004 Jan. 7 p. (Guideline; no. 12). [58 references]

### GUIDELINE STATUS

This is the current release of the guideline.

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Pregnancy and breast cancer

### GUIDELINE CATEGORY

Management  
Risk Assessment

### CLINICAL SPECIALTY

Family Practice  
Obstetrics and Gynecology  
Oncology

## **INTENDED USERS**

Advanced Practice Nurses  
Nurses  
Physician Assistants  
Physicians

## **GUIDELINE OBJECTIVE(S)**

To provide up-to-date information on the management of women with breast cancer who are pregnant or seeking pregnancy after treatment for breast cancer

## **TARGET POPULATION**

Women with breast cancer who are pregnant or seeking pregnancy after treatment for breast cancer

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Management and Treatment**

1. Promotion of breastfeeding to reduce breast cancer risk
2. Deferral of conception (following breast cancer treatment)
3. Treatment of breast cancer during pregnancy
  - Surgery
  - Chemotherapy
  - Radiation therapy
4. Breastfeeding following treatment for breast cancer (note: breastfeeding during chemotherapy or radiotherapy is not recommended)

## **MAJOR OUTCOMES CONSIDERED**

- Incidence of breast cancer during pregnancy
- Risk of breast cancer recurrence
- Survival rates following breast cancer during pregnancy
- Effects of breastfeeding on breast cancer risk

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

A literature search was performed using Medline (1997–2002). The key words used were "breast cancer," "breast neoplasms," "mastectomy," "pregnancy," "pregnancy complications," "breastfeeding," "lactation," "fertility," "infertility," "abortion," "contraception," "contraceptive devices," and "contraceptive agents." Abstracts were used to identify key articles.

## **NUMBER OF SOURCE DOCUMENTS**

Not stated

## **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

## **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

### **Levels of Evidence**

**Ia:** Evidence obtained from meta-analysis of randomised controlled trials

**Ib:** Evidence obtained from at least one randomised controlled trial

**IIa:** Evidence obtained from at least one well-designed controlled study without randomisation

**IIb:** Evidence obtained from at least one other type of well-designed quasi-experimental study

**III:** Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies, and case studies

**IV:** Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities

## **METHODS USED TO ANALYZE THE EVIDENCE**

Review of Published Meta-Analyses  
Systematic Review with Evidence Tables

## **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

## **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

## **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Not stated

## **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

The recommendations were graded according to the level of evidence upon which they were based.

**Grade A** - Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation (evidence levels Ia, Ib)

**Grade B** - Requires the availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendations (evidence levels IIa, IIb, III)

**Grade C** - Requires evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates an absence of directly applicable clinical studies of good quality (evidence level IV)

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

External Peer Review  
Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Following discussion in the Guidelines and Audit Committee, each green-top guideline is formally peer reviewed. At the same time the draft guideline is published on the Royal College of Obstetricians and Gynaecologists (RCOG) website for further peer discussion before final publication.

The names of author(s) and nominated peer reviewers are included in the original guideline document.

# **RECOMMENDATIONS**

## **MAJOR RECOMMENDATIONS**

*In addition to these evidence-based recommendations, the guideline development group also identifies points of best clinical practice in the original guideline document.*

Levels of evidence (**Ia-IV**) and grading of recommendations (**A-C**) are defined at the end of the "Major Recommendations" field.

### **Reproductive Factors and Breast Cancer Risk**

**C** - Women should be advised to breastfeed if possible, as this is likely to reduce their risk of breast cancer in addition to any other benefit.

## **Treatment of Breast Cancer During Pregnancy**

There is no evidence that termination of pregnancy after diagnosis of breast cancer is necessary to improve prognosis.

Treatment during pregnancy will require discussion between the woman, the oncologist, and the obstetrician on the relative benefits of early delivery followed by treatment versus commencement of therapy while continuing the pregnancy. Generally the data for immediate treatment are reassuring, and delay or refusal to undergo therapy has serious consequences.

Although standard protocols are not available, surgery is usually the first-line treatment, with mastectomy or lumpectomy and axillary clearance being the preferred option and deferring reconstruction. [Evidence level III]

Provided that chemotherapy is not used in the first trimester (when it may induce spontaneous miscarriage), it appears to be relatively safe for subsequent use. Although there is a general recommendation to avoid the use of tamoxifen during pregnancy, there is a case report of its use during pregnancy with metastatic breast cancer. The use of radiotherapy to treat breast cancer in pregnancy is not absolutely contraindicated but an appropriate thickness of lead shielding should be used to reduce fetal dose. [Evidence level III]

If chemotherapy is necessary in the first trimester, termination of pregnancy may be proposed. One study advises that, if the cancer is detected in the second trimester and is early-stage, lumpectomy can be followed by chemotherapy and radiation can be withheld until after the birth of the child. In the third trimester, if cancer is detected close to term, it may be possible to defer treatment for a short period and induce delivery. [Evidence level IV]

## **Pregnancy after Treatment of Breast Cancer**

### **Risk of Recurrence**

**C** - Long-term survival after breast cancer does not appear to be affected by pregnancy.

### **Interval Before Attempting Conception**

**C** - It is recommended that pregnancy should be deferred for at least two years after treatment.

As younger women have significantly lower survival rates and higher local and distant relapse rates than older women, those under 33 years of age might be better advised to delay pregnancy for at least three years, to reduce the risk of relapse. [Evidence level III]

One study has recommended that decisions about future conception should be based on the prognosis for the individual woman. They advise that women with stage-IV disease (with a five-year survival of less than 15%) should not consider a pregnancy and that women with stage-III disease should consider deferring

pregnancy for at least five years after treatment. Women with recurrent stage-I or -II tumours should not contemplate conception because of the intensity of the required treatment and the poor prognosis. [Evidence level IV]

### **Fertility Treatment**

There is no current information about the influence of ovarian stimulation on the risk of recurrence in women who have completed treatment for breast cancer.

Increasing numbers of women wish to consider fertility preservation prior to chemotherapy. Embryo freezing is well validated but only suitable for women with a partner. Egg freezing and ovarian tissue cryopreservation are not yet well established and women should be counselled as to the limited success of these approaches. High levels of circulating oestrogen during ovarian stimulation might have an adverse effect on oestrogen-sensitive tumours and this should be considered when counselling oestrogen-receptor positive women prior to chemotherapy.

### **Breastfeeding**

There is no evidence that women who have completed treatment for breast cancer cannot breastfeed safely from the unaffected breast. Breast-conserving surgery may not inhibit lactation but radiotherapy causes fibrosis and lactation is unlikely in an irradiated breast. During treatment for breast cancer with chemotherapy or radiotherapy, women should not breastfeed.

### **Definitions:**

#### **Grading of Recommendations**

**Grade A** - Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation (evidence levels Ia, Ib)

**Grade B** - Requires the availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendations (evidence levels IIa, IIb, III)

**Grade C** - Requires evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates an absence of directly applicable clinical studies of good quality (evidence level IV)

#### **Levels of Evidence**

**Ia:** Evidence obtained from meta-analysis of randomised controlled trials

**Ib:** Evidence obtained from at least one randomised controlled trial

**IIa:** Evidence obtained from at least one well-designed controlled study without randomisation

**IIb:** Evidence obtained from at least one other type of well-designed quasi-experimental study

**III:** Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies, and case studies

**IV:** Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities

## **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations" field).

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Appropriate management of pregnancy in women with or following breast cancer and minimization of risk of cancer recurrence

### **POTENTIAL HARMS**

None stated

## **QUALIFYING STATEMENTS**

### **QUALIFYING STATEMENTS**

- Clinical guidelines are "systematically developed statements which assist clinicians and patients in making decisions about appropriate treatment for specific conditions." Each guideline is systematically developed using a standardised methodology. Exact details of this process can be found in Clinical Governance Advice No. 1: *Guidance for the Development of Royal College of Obstetricians & Gynaecologists (RCOG) Green-top Guidelines*.
- These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Living with Illness  
Staying Healthy

### IOM DOMAIN

Effectiveness  
Patient-centeredness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Royal College of Obstetricians and Gynaecologists (RCOG). Pregnancy and breast cancer. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2004 Jan. 7 p. (Guideline; no. 12). [58 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2004 Jan

### GUIDELINE DEVELOPER(S)

Royal College of Obstetricians and Gynaecologists - Medical Specialty Society

### SOURCE(S) OF FUNDING

Royal College of Obstetricians and Gynaecologists

### GUIDELINE COMMITTEE

Guidelines and Audit Committee

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

*Committee Members:* Professor Deirdre J Murphy, MRCOG (Chair); Lizzy Dijeh (Secretary); Ms Toni Belfield, Consumers' Representative; Professor P R Braude, FRCOG, Chairman, Scientific Advisory Committee; Mrs C Dhillon, Head of Clinical Governance and Standards Dept.; Dr Martin Dougherty, A. Director NCC-WCH; Miss L M M Duley, FRCOG, Chairman, Patient Information Subgroup; Mr Alan S Evans, FRCOG; Dr Mehmet R Gazvani, MRCOG; Dr Rhona G Hughes, FRCOG; Mr Anthony J Kelly MRCOG; Dr Gwyneth Lewis, FRCOG, Department of Health; Dr Mary A C Macintosh, MRCOG, CEMACH; Dr Tahir A Mahmood, FRCOG; Mrs Caroline E Overton, MRCOG, Reproductive medicine; Dr David Parkin, FRCOG; Oncology; Ms Wendy Riches, NICE; Mr Mark C Slack, MRCOG, Urogynaecology; Mr Stephen A Walkinshaw, FRCOG, Maternal and Fetal Medicine; Dr Eleni Mavrides, Trainees Representative

## **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Guideline authors are required to complete a "declaration of interests" form.

## **GUIDELINE STATUS**

This is the current release of the guideline.

## **GUIDELINE AVAILABILITY**

Electronic copies: Available in Portable Document Format (PDF) from the [Royal College of Obstetricians and Gynaecologists \(RCOG\) Web site](#).

Print copies: Available from the Royal College of Obstetricians and Gynaecologists (RCOG) Bookshop, 27 Sussex Place, Regent's Park, London NW1 4RG; Telephone: +44 020 7772 6276; Fax, +44 020 7772 5991; e-mail: [bookshop@rcog.org.uk](mailto:bookshop@rcog.org.uk). A listing and order form are available from the [RCOG Web site](#).

## **AVAILABILITY OF COMPANION DOCUMENTS**

The following are available:

- Guidance for the development of RCOG green-top guidelines. Clinical Governance Advice No 1. 2000 Jan. Available from the [Royal College of Obstetricians and Gynaecologists \(RCOG\) Web site](#).
- Searching for evidence. Clinical Governance Advice No 1. 2001 Oct. Available from the [Royal College of Obstetricians and Gynaecologists \(RCOG\) Web site](#).

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This NGC summary was completed by ECRI on October 17, 2005.

## **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/3/2008

